Acute phase intra-stent tissue reduction effect of prasugrel compared with clopidogrel in patient with acute coronary syndrome
- Conditions
- Acute coronary syndrome
- Registration Number
- JPRN-UMIN000018751
- Lead Sponsor
- Kobe University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Not provided
1. Patients who cannot give informed consent. 2. Absolute contraindications or allergy that cannot be pre-medicated to iodinated contrast or to any of the study medications including both prasgrel and clopidgrel. 3. Contraindications to angiography. 4. If it is known, pregnant or nursing mothers. 5. If it is known, a creatinine clearance <30 mL/min. 6. Previous enrolment in this study. 7. Randomisation or planned use of other investigational drugs or devices in this trial. 8. the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter. 9. insufficient OCT image quality 10. stent thrombosis was developed before secondary OCT 11. cardiac arrest 12. PCI performed on the next day after PCI due to unstable hemodynamic status or chest pain 13. Curprit lesion located in (left main trunk or in )the ostial coronary artery or in a previous stent implantation(stent occulusion or stent restenosis) or in a saphenous vein graft ,in arterial bypass. 14. Stroke was developed after PCI 15. uncontrollable heart failure 16. active bleeding 17. active infection
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary end point of the study was IST score reduction between the 2 treatment groups.
- Secondary Outcome Measures
Name Time Method The secondary end points was the difference in each maximal smooth and irregular IST area reduction between the 2 treatment groups.